Ampio Pharmaceuticals (OTCPK:AMPE) - Aktienkurs, Nachrichten und Analyse

AMPE Aktienübersicht

AMPE grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	3/6
Dividenden	0/6

Risikoanalyse

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Die Erträge sind in den letzten 5 Jahren um 28.4% pro Jahr zurückgegangen

Hat keine nennenswerte Marktkapitalisierung ($85K)

Stark schwankender Aktienkurs in den letzten 3 Monaten

+ 2 mehr Risiken

Ampio Pharmaceuticals, Inc. Wettbewerber

Veritas Farms

OTCPK:VFRM

US$81.9k

CBD Life Sciences

OTCPK:CBDL

US$1.4m

Hero Technologies

OTCPK:HENC

US$563.0

Kid Castle Educational

OTCPK:KDCE

US$357.2k

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Ampio Pharmaceuticals
Historische Aktienkurse
Aktueller Aktienkurs	US$0.0026
52-Wochen-Hoch	US$7.47
52-Wochen-Tief	US$0.000001
Beta	3.71
11 Monat Veränderung	18.18%
3 Monate Veränderung	18.18%
1 Jahr Veränderung	-99.87%
33 Jahre Veränderung	-100.00%
5 Jahre Veränderung	-100.00%
Veränderung seit IPO	-100.00%

Aktuelle Nachrichten und Updates

Recent updates

Here's Why We're Watching Ampio Pharmaceuticals' (NYSEMKT:AMPE) Cash Burn Situation

Feb 17

Aktionärsrenditen

	AMPE	US Pharmaceuticals	US Markt
7D	-74.0%	3.4%	1.6%
1Y	-99.9%	14.2%	32.3%

Rendite im Vergleich zur Industrie: AMPE unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 14.2% erzielte.

Rendite vs. Markt: AMPE hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 32.3 erzielte.

Preisvolatilität

Is AMPE's price volatile compared to industry and market?
AMPE volatility
AMPE Average Weekly Movement	324.1%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: AMPEDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: AMPEDie wöchentliche Volatilität der Aktie ist im letzten Jahr von 1564% auf 324% gesunken, liegt aber immer noch höher als bei 75% der Aktien von US.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
n/a	6	Mike Martino	ampiopharma.com

Ampio Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen, das sich mit der Entwicklung von Therapien zur Behandlung von Kniearthrose (OAK) in den Vereinigten Staaten befasst. Das Unternehmen entwickelt OA-201, eine niedermolekulare Formulierung für die Behandlung von OAK-Schmerzen. Ampio Pharmaceuticals, Inc. hat seinen Sitz in Englewood, Colorado.

Ampio Pharmaceuticals, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Ampio Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
AMPE grundlegende Statistiken
Marktanteil	US$85.27k
Gewinn(TTM)	-US$8.63m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

0.0x

Kurs-Gewinn-Verhältnis

Ist AMPE zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
AMPE Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$0
Bruttogewinn	US$0
Sonstige Ausgaben	US$8.63m
Umsatz	-US$8.63m

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-7.60
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	5.3%

Wie hat sich AMPE auf lange Sicht entwickelt?

Historische Performance und Vergleiche

AMPE Aktienübersicht

Risikoanalyse

Ampio Pharmaceuticals, Inc. Wettbewerber

OTCPK:VFRM

US$81.9k

OTCPK:CBDL

US$1.4m

OTCPK:HENC

US$563.0

OTCPK:KDCE

US$357.2k

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Recent updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension

Levi & Korsinsky Notifies Ampio Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NYSE to Commence Delisting Procedure for Ampio Pharmaceuticals' Common Stock

Glancy Prongay & Murray LLP Files A Class Action Lawsuit Against Ampio Pharmaceuticals, Inc

Robbins LLP Files A Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc

Ampio Pharmaceuticals, Inc., Annual General Meeting, Aug 10, 2022

Ampio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Less than half of directors are independent

Ampio Pharmaceuticals, Inc. Announces Executive Changes

Price target decreased to US$3.50

Ampio Provides Regulatory Update

Ampio Pharmaceuticals Releases Positive Phase 3 Data Analysis for Ampion Targeting Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals Appoints Elizabeth Varki Jobes as Member of the Board and as Member of the Nominating and Corporate Governance Committee of the Board

Less than half of directors are independent

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Ampio Pharmaceuticals, Inc. Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial

Chief Operating Officer exercised options and sold US$111k worth of stock

Ampio Pharmaceuticals, Inc. Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

CFO, Corporate Secretary & Treasurer exercised options and sold US$56k worth of stock

Ampio Pharmaceuticals Reveals Early Positive Results for Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals, Inc. Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion

CFO, Corporate Secretary & Treasurer exercised options to buy US$59k worth of stock.

Here's Why We're Watching Ampio Pharmaceuticals' (NYSEMKT:AMPE) Cash Burn Situation

Ampio Pharmaceuticals, Inc. Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals Provides Update on Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of Covid-19 Patients

Ampio Pharmaceuticals, Inc. Receives Feedback from the FDA on Ampio’s Proposed Modifications to the Special Protocol Asssessment for Ampion Treatment of Severe Osteoarthritis of the Knee

New 90-day high: US$2.76

Ampio Pharmaceuticals, Inc. Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

Ampio Pharmaceuticals, Inc. Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

New 90-day high: US$1.17

Ampio Pharmaceuticals, Inc. Announces the AP-014 Phase I Inhaled Ampion™ Clinical Study In COVID-19 Patients

Ampio Pharmaceuticals, Inc. Announces its Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Begins Phase 1 Clinical Trial of Inhaled Ampion for Covid-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Ampio Pharmaceuticals, Inc. Announces the Receipt of an Investigational New Drug from the U.S. Food and Drug Administration

New 90-day high - US$0.80

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Ampio Pharmaceuticals, Inc.'s Grundlagenzusammenfassung

0.0x

0.0x

Erträge &amp; Einnahmen

Erträge & Einnahmen